Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Feb

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

World Cancer Day 2026 UICCs Campaign United by Unique

Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer

American College of Surgeons Publishes Annual NCDB Report